Research on the Design and Development of Infectious, Inflammatory and Cancer Therapeutics

Dear Colleagues,

Investigating alternative and more effective therapies against human diseases and addressing unmet medical needs is a motivating strategy for patient health care. Infectious diseases, such as tuberculosis, malaria, bacterial infections, particularly MRSA, cancer, or inflammation, such as inflammatory bowel disease and rheumatoid arthritis, are some examples of highly problematic human health challenges. Nanotechnology is a valuable strategy to effectively deliver selective drugs, diagnose diseases, and perform imaging using different delivery systems. Moreover, several nanotechnological approaches have demonstrated benefits in improving the therapeutic performance of newly synthesized molecules or drugs already in clinical use, reducing adverse effects, and enhancing the compound’s physicochemical properties and stability while promoting accumulation at affected tissues. Innovative contrast media and nanomaterials offer a faster and more accurate initial diagnosis. Overall, nanotechnology constitutes a healthcare revolution for managing several pathologies associated with humans.

We invite you to submit original research articles and reviews for this Special Issue. Research areas may include lipidic, polymeric, or metallic drug delivery systems for loading low and high molecular weight molecules, synthetic or natural-derived compounds, enzymes, in vitro 2D and 3D models, and preclinical or clinical studies.

We hope this Special Issue will provide new insights into understanding the progression of infectious, inflammatory, and cancer diseases, develop more effective methods for diagnosis, including imaging, and provide novel nanotechnological therapeutic strategies for treating these pathologies.

We look forward to receiving your contributions.

Dr. Maria Manuela Gaspar
Dr. Catarina Pinto Reis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• drug delivery systems
• liposomes
• polymeric nanoparticles
• metallic nanoparticles
• cancer
• inflammation
• infectious diseases
• in vitro studies
• 2D and 3D models
• in vivo efficacy and safety assessment
• imaging
• diagnosis